December 9th, 2010
Meta-Analysis Finds Aromatase Inhibitors Increase Risk for Heart Disease
Larry Husten, PHD
A new meta-analysis has found that postmenopausal women taking aromatase inhibitors (AIs) instead of tamoxifen to treat breast cancer appear to be at increased risk for cardiovascular complications. The results were presented at the San Antonio Breast Cancer Symposium. Previous studies suggested that women taking AIs were more likely to develop cardiovascular disease, while women taking […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?